- Home
- REVB vs EVOK Comparison
REVB vs EVOK Comparison
Compare REVB & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- EVOK
- Stock Information
- Founded
- REVB 2020
- EVOK 2007
- Country
- REVB United States
- EVOK United States
- Employees
- REVB N/A
- EVOK N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- EVOK Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- EVOK Health Care
- Exchange
- REVB Nasdaq
- EVOK Nasdaq
- Market Cap
- REVB 3.7M
- EVOK 4.2M
- IPO Year
- REVB N/A
- EVOK 2013
- Fundamental
- Price
- REVB $0.75
- EVOK $2.66
- Analyst Decision
- REVB
- EVOK
- Analyst Count
- REVB 0
- EVOK 0
- Target Price
- REVB N/A
- EVOK N/A
- AVG Volume (30 Days)
- REVB 2.9M
- EVOK 18.7K
- Earning Date
- REVB 08-08-2025
- EVOK 08-12-2025
- Dividend Yield
- REVB N/A
- EVOK N/A
- EPS Growth
- REVB N/A
- EVOK N/A
- EPS
- REVB N/A
- EVOK N/A
- Revenue
- REVB N/A
- EVOK $11,594,083.00
- Revenue This Year
- REVB N/A
- EVOK $57.82
- Revenue Next Year
- REVB N/A
- EVOK $59.12
- P/E Ratio
- REVB N/A
- EVOK N/A
- Revenue Growth
- REVB N/A
- EVOK 89.89
- 52 Week Low
- REVB $0.71
- EVOK $1.94
- 52 Week High
- REVB $56.00
- EVOK $14.00
- Technical
- Relative Strength Index (RSI)
- REVB 24.83
- EVOK 39.39
- Support Level
- REVB $0.74
- EVOK $2.46
- Resistance Level
- REVB $0.98
- EVOK $2.84
- Average True Range (ATR)
- REVB 0.06
- EVOK 0.28
- MACD
- REVB 0.07
- EVOK -0.05
- Stochastic Oscillator
- REVB 14.81
- EVOK 15.40
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.